Market-Moving News for April 16th
Market-Moving News for April 16th
CGEM: 23% | Cullinan Therapeutics To Pursue Development Of CLN-978 In Autoimmune Diseases, With Systemic Lupus Erythematosus As First Indication; Discontinued Enrollment In Its B-NHL Study To Focus Ongoing Development On Autoimmune Indications
CGEM：23% | Cullinan Therapeutics 将继续开发 CLN-978 用于自身免疫性疾病，以系统性红斑狼疮为第一适应症；停止招收其 B-NHL 研究，将持续开发重点放在自身免疫适应症上
ITCI: 33% | Intra-Cellular Reports Phase 3 Topline Results From Study 501 Evaluating Lumateperone As Adjunctive Therapy In Patients With Major Depressive Disorder; Lumateperone 42 Mg Met The Primary Endpoint
ITCI：33% | 细胞内报告第501项研究评估卢马佩龙作为重度抑郁症患者的辅助疗法的第3阶段结果；Lumateperone 42 mg达到主要终点
BRTX: 63% | BioRestorative Therapies shares are trading higher after the company announced FDA clearance of its Phase 2 BRTX-100 clinical study protocol amendment.
BRTX：63% | 生物修复疗法公司宣布美国食品药品管理局批准其第二阶段 BRTX-100 临床研究方案修正案后，该公司股价走高。